DoctorDirectory.ai
Menu

Dr. Anand Rohatgi, MD

Not yet claimed

Cardiologist, Preventive cardiologist, Lipidologist · Physician (MD)

Dallas, TX

Not yet claimed. This listing was researched from public sources and screened against our eligibility rules, but the provider has not yet claimed it, verified the details, or attested to guideline-based care. Are you Anand Rohatgi? Claim this profile.

Anand Rohatgi is a cardiologist at UT Southwestern Medical Center in Dallas. He works in preventive cardiology and cholesterol care.

About Dr. Anand Rohatgi, MD

Updated Sep 20, 2026 · next review Dec 19, 2026

Dr. Anand Rohatgi is a cardiologist in Dallas, Texas, who focuses on preventive cardiology and lipid (cholesterol) care. He is a Professor of Medicine in the Division of Cardiology at UT Southwestern Medical Center, where he joined the faculty in 2008, and he is board certified in cardiovascular disease and internal medicine (https://profiles.utsouthwestern.edu/profile/77134/anand-rohatgi.html).

He earned his medical degree at Duke University School of Medicine, completed internal medicine residency at the University of Pennsylvania Health System (2002–2005) and a cardiovascular disease fellowship at UT Southwestern (2005–2008). He also holds a master's degree in clinical science from UT Southwestern (https://www.doximity.com/pub/anand-rohatgi-md, https://profiles.utsouthwestern.edu/profile/77134/anand-rohatgi.html).

Much of his work centers on cholesterol research, including HDL ("good cholesterol") function, and on heart risk in South Asian patients. He is the first author of a New England Journal of Medicine paper on HDL cholesterol efflux capacity and heart events, leads an NIH-funded study on lipoprotein metabolism and cardiometabolic risk in South Asians (2022–2027), and is associated with UT Southwestern's South Asian Heart Program (https://utswmed.org/doctors/anand-rohatgi/, https://reporter.nih.gov/search/bxrtlqfexE65FRfnrwq1PA/project-details/10613478). In March 2026 UT Southwestern announced that he served as co-Chair of the Peer Review Committee for updated national multisociety cholesterol guidance (https://www.utsouthwestern.edu/newsroom/articles/year-2026/march-cholesterol-guideline-shifts-focus-earlier-prevention.html).

CMS Open Payments records list $11,223.31 in industry payments to him across 9 records from 2021 to 2025, with the largest amounts from Horizon Therapeutics ($6,140.39) and CSL Behring ($3,568.75). Payments from drug and device companies to physicians are common and legal, and are reported publicly.

Board certification
Board certified in cardiovascular disease and internal medicine. profiles.utsouthwestern.edu
Professor at UT Southwestern
Professor of Medicine in the Division of Cardiology, Department of Internal Medicine, at UT Southwestern, where he joined the faculty in 2008. profiles.utsouthwestern.edu
Cholesterol guideline role
Served as co-Chair of the Peer Review Committee for updated national multisociety cholesterol guidance, which included input from 11 U.S. expert societies and was announced in March 2026. utsouthwestern.edu
HDL cholesterol research
First author of "HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events" in the New England Journal of Medicine, and co-author of a 2021 Circulation review on future HDL research. utswmed.org
South Asian heart risk work
NIH-funded principal investigator of an R01 study, "Lipoprotein Metabolism and Excess Cardiometabolic Risk in South Asians" (2022–2027). reporter.nih.gov
Hospital affiliations
Affiliated with UT Southwestern Medical Center, UT Southwestern Zale Lipshy Hospital, and Parkland Health. doximity.com
Journal editing
Associate Editor of Circulation and a member of the editorial board of the Journal of Clinical Lipidology; also reviews for journals including The Lancet and JAMA. profiles.utsouthwestern.edu
Society memberships
Fellow of the American College of Cardiology and the American Heart Association, and a member of the National Lipid Association and the American Society for Preventive Cardiology. utswmed.org
Published research volume
About 167 publications are indexed under his name on ResearchGate, including 2026 co-authored papers on nutrition and on cardiovascular events in rheumatoid arthritis. researchgate.net
Industry payments reported
CMS Open Payments lists $11,223.31 in payments across 9 records from 2021 to 2025, led by Horizon Therapeutics ($6,140.39) and CSL Behring ($3,568.75). openpaymentsdata.cms.gov

Industry payments (CMS Open Payments)

Open the CMS record

Federal law requires drug and device companies to report what they pay clinicians: meals, travel, speaking, consulting, and research. Payments are common and legal; the point is that you can see them.

2021 to 2025

$11,223

9 payments

2021$1,525
2022$8,184
2023$1,514
2024$0
2025$0

Top payers

  • Horizon Therapeutics plc$6,140
  • CSL Behring$3,569
  • Janssen Scientific Affairs, LLC$1,500
  • Lilly USA, LLC$14

Payment types

  • Honoraria$6,524
  • Consulting Fee$3,550
  • Travel and Lodging$1,135
  • Food and Beverage$14

A word of caution about these numbers

A payment does not mean your doctor is compromised or acting unethically. Most of these entries are drug samples left for patients, or lunch brought in for the office staff, and the amounts are usually small. Research funding and speaking at medical meetings are also normal parts of a clinical career.

As a rough guide, a total under $15,000 a year is usually not a concern. Much larger sums, especially from one company whose product your doctor recommends to you, are worth asking about. You are allowed to ask.

Sources: health.usnews.com · utswmed.org · profiles.utsouthwestern.edu · utswmed.org · doximity.com · healthgrades.com · researchgate.net · reporter.nih.gov. Something wrong or out of date? Tell us and we will correct it.

Summary prepared with AI assistance from the public sources linked above, reviewed every three months. It is not a review, a rating, or an endorsement.

Practice location

Something wrong with this profile? ·